US FDA approves Regeneron's rare bone disorder drug. Regeneron's Pasatru has received US FDA approval for adults with FOP after clinical trials showed a significant reduction in abnormal bone formation. By Reuters August 20, 2026, 8:59:40 AM IST (Published) The US FDA on Wednesday (August 19) approved Regeneron's drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues. New York-based Regeneron's shares rose 4%. The drug, garetosmab, branded as Pasatru, was approved to treat adults with fibrodysplasia ossificans progressiva (FOP) - a condition in which muscle, tendon and ligament tissue gradually turns into bone, leading to a "second skeleton" that causes progressive loss of mobility and reduced life expectancy. In a 56-week trial involving 63 participants, Pasatru reduced the development of new bone abnormalities by 94% in patients treated with a 3 mg per kg dose and by 90% in those given a 10 mg per kg dose, compared with a placebo. The drug works by blocking Activin A, a protein involved in triggering abnormal bone growth in patients with FOP. Susan Rhee, a member of Regeneron's clinical team, told Reuters last week that the company plans to start a trial for children later this year. The drug will compete with French drugmaker Ipsen's oral treatment Sohonos, which in 2023 became the only other treatment approved by the US Food and Drug Administration. Incyte and partner Mirum Pharma, as well as privately held Ashibio, are also developing treatments for the condition. In 2020, Regeneron paused dosing in a mid-stage trial of the drug after five patient deaths, ultimately discontinuing the study and working with global regulators to design the late-stage trial, according to the company. The condition affects roughly 1 in 2 million people worldwide, with around 800 to 900 active diagnosed cases globally, according to data from the National Institutes of Health.

Global Vitiligo Foundation applauds Incyte's "Moments of Clarity" Campaign for elevating patient voices and advancing vitiligo awareness. MECHANICSBURG, Pa.-(BUSINESS WIRE)-The Global Vitiligo Foundation (GVF) proudly recognizes and supports Incyte's Moments of Clarity campaign, a powerful storytelling initiative that highlights the lived experiences of individuals with nonsegmental vitiligo. Through authentic patient narratives, the campaign closely aligns with GVF's mission to improve the quality of life for people affected by vitiligo through education, advocacy, and community connection. Moments of Clarity captures pivotal turning points in patients' journeys - from recognizing the need for support, to seeking care, to experiencing meaningful progress in managing their condition. These stories not only raise awareness of vitiligo but also foster understanding, empowerment, and hope within the global vitiligo community. "This campaign reflects the heart of what GVF stands for: ensuring that people living with vitiligo feel seen, supported, and empowered," said Seemal R. Desai, MD, President of the Global Vitiligo Foundation. "By elevating real voices and real journeys, Moments of Clarity helps break down stigma while reinforcing the importance of informed care and community connection." This year, Incyte introduces three new stories from patients who exemplify the resilience and self-discovery of the nonsegmental vitiligo treatment process as they experience meaningful improvement in their condition with Opzelura(R)(ruxolitinib) cream 1.5%: * Carolyn, who gave Opzelura a second try and learned that persistence and patience are key to seeing results with treatment. By staying consistent and connecting with the vitiligo community, she is now achieving her personal treatment goals. * Tiffanie, diagnosed at age 7, who embraced a journey of self-love over decades before choosing to explore treatment. Inspired by her grandmother's courage, she now channels her experience into advocacy through the I AM GREAT MOVEMENT. * Kasey, a mother and sports enthusiast, who spent years concealing her vitiligo before reclaiming her confidence. Now working at Incyte as a sales representative, she uses her personal experience to help others find hope and a sense of control. "These stories reflect the diversity of the vitiligo experience and highlight the importance of individualized journeys," Dr. Desai added. "They reinforce that treatment decisions are deeply personal and that support systems, whether clinical or community-based, play a vital role in overall well-being." GVF's vision is a world where the burden of vitiligo is eliminated through compassion, care, and cure. Initiatives like Moments of Clarity contribute meaningfully to that vision by increasing public awareness, encouraging patient engagement, and promoting conversations around care options and emotional well-being. GVF is proud to have Incyte as a sponsor in support of the global vitiligo community. The Global Vitiligo Foundation encourages patients, caregivers, and healthcare providers to explore these inspiring stories and learn more about the journeys of individuals living with nonsegmental vitiligo by visiting www.mymomentsofclarity.com. Together, through education, storytelling, and collaboration, GVF and partners like Incyte continue to advance a more informed, compassionate, and hopeful future for the vitiligo community. About the Global Vitiligo Foundation The Global Vitiligo Foundation (GVF) is a nonprofit organization dedicated to improving the lives of people with vitiligo through research, education, advocacy, and support. GVF works to increase public understanding, promote collaboration among experts, and empower individuals affected by vitiligo to thrive.

Incyte (NASDAQ:INCY) EVP sells $5,005,254.54 in stock. August 4, 2026 Key points. * Incyte EVP Patrick Mayes sold 41,899 shares for approximately $5.01 million at an average price of $119.46 under a pre-arranged Rule 10b5-1 trading plan, reducing his direct holdings by 40.54% to 61,441 shares. * Incyte shares rose 1.9% to $120.65, while the company's latest quarterly results exceeded expectations: earnings were $3.09 per share versus a $2.15 estimate, and revenue increased 37.7% year over year to $1.67 billion. * Analyst sentiment is mixed, with a consensus "Hold" rating and a $120.40 price target; targets range from $109 to $155, while institutional investors own 96.97% of the company. * Five stocks to consider instead of Incyte. Incyte Corporation (NASDAQ:INCY - Get Free Report) EVP Patrick Mayes sold 41,899 shares of the company's stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $119.46, for a total transaction of $5,005,254.54. Following the completion of the sale, the executive vice president directly owned 61,441 shares of the company's stock, valued at $7,339,741.86. The trade was a 40.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Incyte stock up 1.9%. INCY stock traded up $2.22 during trading on Tuesday, hitting $120.65. 2,052,860 shares of the company's stock traded hands, compared to its average volume of 1,796,887. The firm has a market capitalization of $24.46 billion, a P/E ratio of 15.37, a PEG ratio of 3.96 and a beta of 0.76. Incyte Corporation has a 1 year low of $76.45 and a 1 year high of $132.60. The business has a fifty day simple moving average of $109.97 and a two-hundred day simple moving average of $102.32. Incyte (NASDAQ:INCY - Get Free Report) last posted its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share for the quarter, topping analysts' consensus estimates of $2.15 by $0.94. The company had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.50 billion. Incyte had a return on equity of 29.93% and a net margin of 27.71%.Incyte's revenue was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.57 earnings per share. On average, equities research analysts predict that Incyte Corporation will post 2.5 EPS for the current fiscal year. Institutional trading of Incyte. Institutional investors have recently made changes to their positions in the business. Jacobi Capital Management LLC grew its stake in Incyte by 0.9% during the fourth quarter. Jacobi Capital Management LLC now owns 10,613 shares of the biopharmaceutical company's stock worth $1,048,000 after buying an additional 99 shares during the period. Oregon Public Employees Retirement Fund raised its stake in shares of Incyte by 0.5% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 18,870 shares of the biopharmaceutical company's stock valued at $1,864,000 after acquiring an additional 100 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of Incyte by 7.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,628 shares of the biopharmaceutical company's stock valued at $161,000 after acquiring an additional 113 shares in the last quarter. Bank of Nova Scotia lifted its holdings in shares of Incyte by 0.7% during the 2nd quarter. Bank of Nova Scotia now owns 17,041 shares of the biopharmaceutical company's stock valued at $1,160,000 after acquiring an additional 124 shares in the last quarter. Finally, Perbak Capital Partners LLP boosted its position in Incyte by 2.5% during the 3rd quarter. Perbak Capital Partners LLP now owns 5,298 shares of the biopharmaceutical company's stock worth $449,000 after purchasing an additional 129 shares during the period. Institutional investors and hedge funds own 96.97% of the company's stock. Analyst upgrades and downgrades. INCY has been the subject of a number of analyst reports. Stifel Nicolaus set a $145.00 price objective on Incyte in a research note on Tuesday, July 28th. Leerink Partners lifted their target price on Incyte from $131.00 to $155.00 and gave the company an "outperform" rating in a research note on Monday. Royal Bank Of Canada boosted their target price on shares of Incyte from $99.00 to $109.00 and gave the stock a "sector perform" rating in a report on Wednesday, July 29th. BMO Capital Markets raised their price target on shares of Incyte from $112.00 to $130.00 and gave the company a "market perform" rating in a report on Wednesday, July 29th. Finally, Oppenheimer reaffirmed a "market perform" rating and issued a $120.00 price objective on shares of Incyte in a research report on Tuesday, July 28th. Ten equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat.com, Incyte currently has a consensus rating of "Hold" and a consensus price target of $120.40. Discover more Market Cap Calculator Business News AI Stocks Report About Incyte. Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases. The company's flagship product is Jakafi(R)(ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Incyte, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list. While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.